<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898585</url>
  </required_header>
  <id_info>
    <org_study_id>ML28711</org_study_id>
    <nct_id>NCT01898585</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma</brief_title>
  <official_title>An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, single-arm, multicenter study will assess the safety and efficacy of&#xD;
      Zelboraf (vemurafenib) in patients with Braf V600 mutation positive metastatic melanoma.&#xD;
      Patients will receive Zelboraf 960 mg twice a day until progressive disease, unacceptable&#xD;
      toxicity, consent withdrawal, death, reasons deemed by the treating physician or study&#xD;
      termination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2013</start_date>
  <completion_date type="Actual">May 22, 2019</completion_date>
  <primary_completion_date type="Actual">May 22, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate according to Response evaluation criteria in solid tumors (RECIST v1.1)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Zelboraf Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zelboraf</intervention_name>
    <description>Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.</description>
    <arm_group_label>Zelboraf Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults patients &gt;= 18 years of age&#xD;
&#xD;
          -  Patients with histologically confirmed metastatic melanoma (surgically incurable and&#xD;
             unresectable stage IIIC or stage IV; AJCC) with documented BRAF V600 mutation&#xD;
             determined by the cobasÂ® BRAF V600 Mutation Test prior to administration of&#xD;
             vemurafenib. Unresectable stage IIIC disease must have confirmation from a surgical&#xD;
             oncologist&#xD;
&#xD;
          -  Patients with either measurable or non-measurable disease (RECIST Version 1.1)&#xD;
&#xD;
          -  Patients may or may not have received prior systemic therapy for metastatic melanoma&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2&#xD;
&#xD;
          -  Patients must have recovered from all side effects of their most recent systemic or&#xD;
             local treatment for metastatic melanoma&#xD;
&#xD;
          -  Adequate hematological, renal, and liver function&#xD;
&#xD;
          -  Negative serum pregnancy test at screening&#xD;
&#xD;
          -  Fertile men and women must use an effective form of contraception during the study and&#xD;
             for at least 6 months after completion of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of symptomatic CNS lesions as determined by the investigator, use of steroid&#xD;
             or anti-seizure medication for treatment of brain metastases prior to the first&#xD;
             administration of vemurafenib&#xD;
&#xD;
          -  Patients with previous malignancies (other than melanoma) within the past 2 years&#xD;
             except patients with treated and controlled basal or squamous cell carcinoma (SCC) of&#xD;
             the skin or carcinoma in-situ of the cervix.&#xD;
&#xD;
          -  Concurrent administration of any anti-cancer therapies (e.g. chemotherapy, other&#xD;
             targeted therapy, experimental drug, etc.) other than those administered in this study&#xD;
&#xD;
          -  Known hypersensitivity to vemurafenib or another BRAF inhibitor&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant&#xD;
             bowel resection that would preclude adequate absorption.&#xD;
&#xD;
          -  Any of the following within the 6 months prior to the first vemurafenib&#xD;
             administration: myocardial infarction, severe/unstable angina, symptomatic congestive&#xD;
             heart failure, cerebrovascular accident or transient ischaemic attack, pulmonary&#xD;
             embolism, hypertension not adequately controlled by current medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Hospital; Oncotherapy Dept</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital ( Uni of Capetown ); Oncology Dept</name>
      <address>
        <city>Cape Town</city>
        <zip>7506</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Town Oncology Trials</name>
      <address>
        <city>Cape Town</city>
        <zip>7570</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancercare</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancercare</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Potter Oncology Centre</name>
      <address>
        <city>Groenkloof</city>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Centre of Rosebank; Oncology</name>
      <address>
        <city>Johannesburg</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pretoria; Department of Medical Oncology</name>
      <address>
        <city>Pretoria</city>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Medical Group</name>
      <address>
        <city>Sandton</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 9, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vemurafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

